# Acceptability/Tolerance of Protein Substitutes in Tablet Form for the Dietary Management of Rare Aminoacidopathies

> **NCT06298292** · — · NOT_YET_RECRUITING · sponsor: **metaX Institut fuer Diatetik GmbH** · enrollment: 15 (estimated)

## Conditions studied

- Tyrosinemia, Type I
- Tyrosinemia, Type II
- Tyrosinemia, Type III
- Alkaptonuria
- Homocystine; Metabolic Disorder
- MSUD (Maple Syrup Urine Disease)

## Interventions

- **DIETARY_SUPPLEMENT:** Zero minis (range of protein substitutes in tablet form)

## Key facts

- **NCT ID:** NCT06298292
- **Lead sponsor:** metaX Institut fuer Diatetik GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-04-01
- **Primary completion:** 2026-03-31
- **Final completion:** 2026-06-30
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2024-03-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06298292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06298292, "Acceptability/Tolerance of Protein Substitutes in Tablet Form for the Dietary Management of Rare Aminoacidopathies". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06298292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*